Literature DB >> 33389342

Duration and choices of prophylactic anticonvulsants in subarachnoid hemorrhage: a systematic review and meta-analysis.

Yuqi Chen1, Fan Xia1, Chengzhi Cai2, Hao Li1, Lu Ma1, Xin Hu3, Chao You1.   

Abstract

The use of prophylactic anticonvulsants among patients with subarachnoid hemorrhage (SAH) is controversial. We sought to assess the effectiveness of different durations of prophylactic antiepileptic drug (AED) use among SAH patients. We searched the MEDLINE, Embase, Cochrane, and ClinicalTrials.gov databases until March 1, 2020. Randomized controlled trials or observational studies comparing different durations or different drugs were selected. The primary outcome was poor clinical outcomes. The secondary outcome was in-hospital seizure. Bayesian network meta-analysis was also performed to indirectly compare the effectiveness of different prophylaxes. A total of 5 papers were included. Three studies with a total of 959 patients were included in the analysis of the primary outcome; the results showed that long-term exposure to prophylactic AEDs (more than 3 days) led to poor clinical outcomes (OR 1.55; 95% CI 1.01-2.39; p = 0.045). Four studies with 1024 patients were included in the analysis of the secondary outcome; the results showed no association between the duration of prophylactic AED use and the occurrence of in-hospital seizures (OR 0.62; 95% CI 0.18-2.15; p = 0.447). In the network meta-analysis, no significant difference was found among the four different prophylaxes. Our findings suggested that, when compared with the short-term use, the long-term use of prophylactic AEDs in SAH patients has a similar effect on in-hospital seizure prevention but is associated with poor clinical outcomes. However, these findings were based on a small number of available studies with obvious heterogeneity in study design and different prescription regimens. Further well-designed studies are warranted to elucidate these questions.

Entities:  

Keywords:  Anticonvulsants; Duration; Poor clinical outcomes; Seizure; Subarachnoid hemorrhage

Year:  2021        PMID: 33389342     DOI: 10.1007/s10143-020-01466-1

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  15 in total

1.  Three-day phenytoin prophylaxis is adequate after subarachnoid hemorrhage.

Authors:  Sorayouth Chumnanvej; Ian F Dunn; Dong H Kim
Journal:  Neurosurgery       Date:  2007-01       Impact factor: 4.654

2.  Comparison of short-duration levetiracetam with extended-course phenytoin for seizure prophylaxis after subarachnoid hemorrhage.

Authors:  Theresa Murphy-Human; Emily Welch; Gregory Zipfel; Michael N Diringer; Rajat Dhar
Journal:  World Neurosurg       Date:  2011-02       Impact factor: 2.104

3.  A Randomized Trial of Brief Versus Extended Seizure Prophylaxis After Aneurysmal Subarachnoid Hemorrhage.

Authors:  Theresa Human; Michael N Diringer; Michelle Allen; Gregory J Zipfel; Michael Chicoine; Ralph Dacey; Rajat Dhar
Journal:  Neurocrit Care       Date:  2018-04       Impact factor: 3.210

4.  Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage.

Authors:  Andrew M Naidech; Kurt T Kreiter; Nazli Janjua; Noeleen Ostapkovich; Augusto Parra; Christopher Commichau; E Sander Connolly; Stephan A Mayer; Brian-Fred M Fitzsimmons
Journal:  Stroke       Date:  2005-01-20       Impact factor: 7.914

5.  Prophylactic Antiepileptics and Seizure Incidence Following Subarachnoid Hemorrhage: A Propensity Score-Matched Analysis.

Authors:  David Panczykowski; Matthew Pease; Yin Zhao; Gregory Weiner; William Ares; Elizabeth Crago; Brian Jankowitz; Andrew F Ducruet
Journal:  Stroke       Date:  2016-06-14       Impact factor: 7.914

6.  Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/american Stroke Association.

Authors:  E Sander Connolly; Alejandro A Rabinstein; J Ricardo Carhuapoma; Colin P Derdeyn; Jacques Dion; Randall T Higashida; Brian L Hoh; Catherine J Kirkness; Andrew M Naidech; Christopher S Ogilvy; Aman B Patel; B Gregory Thompson; Paul Vespa
Journal:  Stroke       Date:  2012-05-03       Impact factor: 7.914

7.  Utility of levetiracetam in patients with subarachnoid hemorrhage.

Authors:  Dharmen Shah; Aatif M Husain
Journal:  Seizure       Date:  2009-10-27       Impact factor: 3.184

8.  Outcome in patients with subarachnoid hemorrhage treated with antiepileptic drugs.

Authors:  Axel J Rosengart; J Dezheng Huo; Jocelyn Tolentino; Roberta L Novakovic; Jeffrey I Frank; Fernando D Goldenberg; R Loch Macdonald
Journal:  J Neurosurg       Date:  2007-08       Impact factor: 5.115

9.  Epilepsy-associated long-term mortality after aneurysmal subarachnoid hemorrhage.

Authors:  Jukka Huttunen; Antti Lindgren; Mitja I Kurki; Terhi Huttunen; Juhana Frösen; Timo Koivisto; Mikael von Und Zu Fraunberg; Arto Immonen; Juha E Jääskeläinen; Reetta Kälviäinen
Journal:  Neurology       Date:  2017-06-14       Impact factor: 9.910

10.  Seizure Prophylaxis in the Immediate Post-Hemorrhagic Period in Patients with Aneurysmal Subarachnoid Hemorrhage.

Authors:  Thomas V Kodankandath; Salman Farooq; Wled Wazni; John-Andrew Cox; Christopher Southwood; Gregory Rozansky; Vijay Johnson; John R Lynch
Journal:  J Vasc Interv Neurol       Date:  2017-12
View more
  2 in total

1.  Pharmaceutical Management for Subarachnoid Hemorrhage.

Authors:  Arnav Barpujari; Chhaya Patel; Rebecca Zelmonovich; Alec Clark; Devan Patel; Kevin Pierre; Kyle Scott; Brandon Lucke Wold
Journal:  Recent Trends Pharm Sci Res       Date:  2021

2.  Seizure prophylaxis following aneurysmal subarachnoid haemorrhage (SPSAH): study protocol for a multicentre randomised placebo-controlled trial of short-term sodium valproate prophylaxis in patients with acute subarachnoid haemorrhage.

Authors:  Yuqi Chen; Mei Fang; Pei Wu; Zhiyi Xie; Honggang Wu; Qiaowei Wu; Shancai Xu; Yuchen Li; Bowen Sun; Bo Pang; Niandong Zheng; Jianmin Zhang; Xin Hu; Chao You
Journal:  BMJ Open       Date:  2022-05-04       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.